



## Original Research Article

Antibiotic susceptibility patterns of *Pseudomonas sp.* isolated from various clinical samples at a tertiary care hospital at Dewas in Madhya Pradesh, IndiaSandeep Negi<sup>1</sup>, Ramanath K<sup>2</sup>, Lakshmi Bala<sup>1</sup>, Munesh Kumar Sharma<sup>3,\*</sup><sup>1</sup>Dept. of Biochemistry, Babu Banarasi Das University, Lucknow, Uttar Pradesh, India<sup>2</sup>Dept. of Microbiology, Index Medical College Hospital and Research Centre, Indore, Madhya Pradesh, India<sup>3</sup>Dept. of Microbiology, Amaltas Institute of Medical Sciences, Dewas, Madhya Pradesh, India

## ARTICLE INFO

## Article history:

Received 17-01-2021

Accepted 23-02-2021

Available online 02-04-2021

## Keywords:

Antibiotic susceptibility test (AST)

Kirby-Bauer disc diffusion method

*Pseudomonas aeruginosa*

Multiple drug resistance (MDR)

Extended-spectrum  $\beta$ -lactamase

(ESBL)

## ABSTRACT

**Background:** A significant proportion of nosocomial infections is contributed by the *Pseudomonas sp.* Major changes were observed from time to time in *Pseudomonas sp.* prevalence and multidrug-resistant (MDR) with enormous morbidity and mortality. The spread of antimicrobial resistance has now become a worldwide issue as a consequence of the haphazard use of antimicrobials.

**Place and duration:** This study was done in the Amaltas Institute of Medical Sciences from February 2019 to December 2019.

**Materials and Methods:** *Pseudomonas sp.* was isolated from different clinical samples like urine, sputum, pus, fluid, and catheter tip. Identification of *Pseudomonas sp.* was done by biochemical tests. Antibiotic susceptibility test (AST) was done by Kirby-Bauer disc diffusion method. Data Analysis was done by percentage method. Extended-spectrum  $\beta$ -lactamase (ESBLs) production was detected by the combined disc diffusion test.

**Results:** Sensitivity was seen in colistin and polymyxin B - 100%, meropenem - 86.58% and piperacillin-tazobactam - 82.92%. Resistance was seen in co-trimoxazole- 80.48%, cefixime- 82.92%, cefoperazone/sulbactam-59.75% and ciprofloxacin- 39.02%. The maximum number of MDR strains were isolated from the pus samples (n=18) as compared to other samples. The total number of ESBL producing strains was seen higher in the pus samples (n=15). The number of *P. aeruginosa* strains (n=57) was seen greater in number than other *Pseudomonas sp.*

**Conclusion:** The present study is an attempt to regulate the use of antibiotics that are irrelevant and wasteful. It is also a public health concern to take adequate measures, maintain cleanliness and hygiene to reduce the spread of nosocomial infections.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## 1. Introduction

*Pseudomonas* is an ultimate example of the opportunistic nosocomial pathogen, which in immuno-compromised patients causes a broad range of infections and contributes to severe morbidity. The mortality due to nosocomial pseudomonal pneumonia is around 70 percent, despite therapy.<sup>1</sup> Sadly, *P. aeruginosa* displays resistance to several antibiotics, thus endangering the option of effective therapy.<sup>2</sup> In isolates that are multidrug tolerant, the relative

contributions to phenotypic multidrug resistance from various molecular pathways are not well-known. While several surveillance studies have been performed over the years to control the resistance of *Pseudomonas sp.* to different antimicrobial agents, studies identifying trends in concurrent resistance to various antibiotics over time are rare.<sup>3,4</sup> One of the most serious complications associated with *Pseudomonas* is antibiotic resistance. Due to their ability to be naturally resistant to several pathogens, a limited number of antibiotics are successful.<sup>5</sup> Most gram-negative bacteria (including *Pseudomonas*) are responsible

\* Corresponding author.

E-mail address: [muneshmanipal@gmail.com](mailto:muneshmanipal@gmail.com) (M. K. Sharma).

for the production of ESBL, which shows resistance to many antibiotics of new generations.<sup>6</sup> Very little data is available regarding the pattern of resistance of antibiotic drugs to *Pseudomonas sp.* in the Dewas, Madhya Pradesh. Therefore, we study the pattern of antibiotic resistance of *Pseudomonas sp.*, as it is the first study in the tertiary care hospital of the Dewas region of Madhya Pradesh, India.

## 2. Materials and Methods

The present study was done at the Amaltas Institute of Medical Sciences, Dewas, Madhya Pradesh. It begins from February 2019 to December 2019. In this study total of 82 strains of *Pseudomonas sp.* were isolated from different clinical samples (Urine, sputum, pus, fluid, and Catheter tip samples) in the tertiary care hospital. Identification of *Pseudomonas sp.* was done by biochemical tests. Antibiotic susceptibility test (AST) method was done by Kirby-Bauer disc diffusion method as per CLSI (clinical and laboratory standards institute) criteria.<sup>7</sup> All the analysis was performed using the simple percentage method.<sup>7,8</sup>

### 2.1. Identification of *Pseudomonas sp.*

All clinical samples collected were inoculated aseptically on MacConkey agar and Blood agar media plates in case of urine and pus samples while an additional chocolate agar plate was used in case of sputum samples which were incubated at 37°C for 24 Hrs. Urine samples were inoculated by using a 4mm inoculating loop. In the case of the urine sample, 10<sup>5</sup>CFU/ml of growth was considered for significant bacteriuria. Further *Pseudomonas sp.* was identified by cultural characteristics, morphological characteristics.<sup>9</sup>

### 2.2. Identification of *Pseudomonas sp.* was done by biochemical tests.

Biochemical tests:- *Pseudomonas sp.* indicated Oxidase positive reaction. In mannitol test showed strong motility. The color of citrate converted to blue from green indicated a positive reaction. The urease tube remains unchanged indicates a negative reaction. Triple sugar iron (TSI) indicated alkaline slant /no change in the butt. Species identification of *Pseudomonas* was performed by the Oxidative-Fermentative (O-F) test for Glucose, sucrose, lactose, and mannitol; Liquefaction of gelatin, by beta hemolysis on a blood agar plate and test for nitrate reduction. The urease hydrolysis is also used for its identification. Other tests include decarboxylation of Arginine, Lysin, and Ornithine. The growth at 35 °C and at 42° C for a time duration of 18-24 hours on two tubes of trypticase soy agar (TSA).<sup>10</sup>

### 2.3. Antibiotic susceptibility test

Antibiotic susceptibility test (AST) method was done by Kirby-Bauer disc diffusion method on *Pseudomonas sp.* following the guidelines of the Clinical Laboratory Standards Institute 2015.<sup>11</sup> First, the inoculums were prepared for AST with the help of nutrient broth by taking 5/6 colony of *Pseudomonas sp.* that matched to 0.5 McFarland standard (1.5x10<sup>8</sup>CFU/ml) within 15 minutes, a sterile cotton swab was dipped into the inoculums suspension and pressed inside the wall of the tube above the fluid level, and inoculate over the dried surface of Mueller Hinton Agar (MHA) plate. After 3-5 minutes antibiotic discs were applied and gently pressed down to ensure complete contact with agar. The antibiotic disc used for AST in present study were purchased from Hi-media laboratories; co-trimoxazole (25µg), ciprofloxacin (5µg), ceftazidime (30µg), cefixime(30µg), gentamicin (10µg), amikacin(30µg), meropenem(10µg), cefoperazone/sulbactam (75/3030µg), piperacillin - tazobactam(100/10µg), colistin(10µg), polymyxin-B(300unit), piperacillin (100µg), tobramycin(10µg), cefotaxime(30µg) and amoxicillin/clavulanic acid (30µg). Zone of inhibition was measured in mm was concluded with interpretative criteria CLSI 2015<sup>11</sup> and isolates were sensitive, intermediate, and resistant. *Pseudomonas aeruginosa* ATCC-27853 was used as a control strain.<sup>11</sup>

### 2.4. Identification of extended-spectrum β-lactamase (ESBL) producing strains

ESBL producers isolates were identified as resistant to antibiotics like ceftazidime, cefotaxime, and ceftriaxone in AST.<sup>12</sup> Further confirmation for ESBL producing Strains was done by placing the amoxicillin/clavulanic acid at the center and on sides, ceftazidime and cefotaxime were placed 25 mm apart from center to center on inoculated MHA plate. The incubation of the MHA plate was done at 37°C for 18-24 hrs. The inoculums that showed zone of inhibition with synergism in between amoxicillin/clavulanic acid and cefotaxime or ceftazidime was confirmed ESBL producers.<sup>8</sup>


### 2.5. Ethical clearance

No ethical clearance was required in this study as it was done on stored refrigerated bacterial isolates.


## 3. Results

The total number of isolates of *Pseudomonas sp.* collected were 82. Gender wise distribution of isolates were male (56.01%) and female (43.9%) patients, as shown in figure 1(A). The sample distribution for collected isolated was Pus 54.87%, Urine 32.92%, Sputum 6%, Fluid 2.43% and catheter tip 3.65%, as shown in


figure 1(B). Out of total 82 isolates of 54(65.85%) isolates of *Pseudomonas sp.* collected from inpatients (IPD samples) whereas 28(34.15%) isolates collected from outpatients(OPD samples)as shown in figure 2. The highest number of isolates of *Pseudomonas sp.* were collected from patients at age interval between 31 to 45 years (33 isolates), as shown in figure 3. In every age group isolates collected from male patients was greater than female patients. Morphology of *Pseudomonas sp.* are in gram-negative rods belongs to the family of Enterobacteriaceae, as shown in figure 4. Sensitivity was seen 100% (n=82) in colistin and polymyxin-B, 86.58% (n=71) in meropenem, 82.92% (n=68) in piperacillin -tazobactam, 68.29%(N=56) in tobramycin, 67.07% (n=55) in gentamicin, 64.63%(n=53) in amikacin, 58.58%(n=48) in piperacillin, 56.09%(n=46) in ceftazidime and 51.21%(n=42) in ciprofloxacin, as shown in the figure 6. Resistance was seen 80.48% (N=66) in co-trimoxazole, 82.92% (n=68) in cefixime, 59.75% (n=49) in cefoperazone/sulbactam, 39.02%(n=32) in ciprofloxacin and 36.58%(n=30) in piperacilin, as shown in the figure 7. The maximum number of MDR strains were isolated from the pus samples (n=18) as compared to other samples. MDR strains were seen higher in males than females in the case of pus samples, whereas females were seen in greater numbers than males in urine samples, as shown in figure 8(B). The total number of ESBL producing strains of *Pseudomonas sp.* in clinical samples was 30.48%(n=25). The distribution of ESBL strains of *Pseudomonas sp.* in clinical samples was pus 60%(n=25), urine 36%(n=9), and catheter tip 4%(n=4), as shown in figure 9. The ESBL strains were seen higher in number in the pus sample as compared to other samples. From the total strains, the number of *Peudomonas aeruginosa* strains (n=57, 69.51%) was seen as greater than other species, as shown in figure 10.



**Fig. 2:** Percentage of inpatient (IPD) and outpatients (OPD) samples




**Fig. 3:** Age distribution of patients




**Fig. 1:** (A) Gender wise distribution of samples (B) Clinical sample distribution

**4. Discussion**

In the present study, maximum isolates of *Pseudomonas sp.* were found in pus samples (54.87%) followed by urine samples (32.92%), similar findings were reported by Khan et al. (2008)<sup>13</sup> isolated maximum pus sample (57.64%) followed by urine (24.2%). In another study by



**Fig. 4:** (A) *Pseudomonas sp.* gram stain (B) *P. aeruginosa* growth in Nutrient Agar (C) Pigment producing *Pseudomonas sp.* in MHA plate





**Fig. 5:** Biochemical tests for identification of *Pseudomonas sp*



**Table 1:**


Antibiotic Name	Sensitivity		Intermediate		Resistance	
	NS	%	NI	%	NR	%
Co-trimoxazole	11	13.41	5	6.09	66	80.48
Ciprofloxacin	42	51.21	8	9.75	32	39.02
Ceftazidime	46	56.09	6	7.31	30	36.58
Cefixime	4	4.87	10	12.19	68	82.92
Gentamicin	55	67.07	7	8.53	20	24.39
Amikacin	53	64.63	8	9.75	21	25.6
Meropenem	71	86.58	4	4.87	7	8.53
Cefoparazone-salbactam	21	25.6	12	14.63	49	59.75
Piperacillin-tazobactam	68	82.92	3	3.65	11	13.41
Colistin	82	100	0	0	0	0
Polymyxin-B	82	100	0	0	0	0
Piperacillin	48	58.53	4	4.87	30	36.58
Tobramycin	56	68.29	7	8.53	19	23.17

\*NS- Number of Sensitive strains, NI- Number of Intermediate strains, NR – Number of resistant strains

**Fig. 6:** *Pseudomonas sp* Sensitivity to different Antibiotic drugs**Fig. 7:** *Pseudomonas sp* Resistance to different Antibiotic drugs

Mohanasoundaram (2011)<sup>14</sup> also showed higher isolates from pus samples followed by urine samples. A recent study by Nabamita Chaudhury et al., (2018)<sup>15</sup> reported maximum isolates were isolated from pus samples(42.62%). In the present study, maximum isolates were found in the age interval between 31 to 45 years (40.24%). Previous research findings by Mohanasoundaram (2011)<sup>14</sup> have reported the highest numbers of isolates of *Pseudomonas* in different age groups. So there is no significant relationship in the age of the patient with infection of *Pseudomonas* as it

**Fig. 8:** (A): *Pseudomonas sp.* showing multiple drug resistance (B): Distribution of *Pseudomonas sp* in samples of different sex**Fig. 9:** Distribution of isolated strains of *Pseudomonas sp.* from clinical samples



**Fig. 10:** Distribution of ESBL strains of *Pseudomonas sp.* in clinical samples

varies in different studies. In the present study, we showed the isolates of *Pseudomonas sp.* were maximum in male patients in the case of all types of samples. This outcome is consistent with a previous study by Khan et al., (2008),<sup>13</sup> which found that 61.78% of males and 38.22% of females were infected with *Pseudomonas*. Many studies have shown that infection with the *Pseudomonas sp.* is more prevalent in men than in women by Ullah et al., (2019).<sup>16</sup> In the present study, in-patients samples (65.85%) showed the maximum *Pseudomonas* isolates as compared to outpatients samples (34.15%). Mohanasoundaram, (2011)<sup>14</sup> reported in the previous study align with the current study as they registered the highest number of inpatient cases, with 35.86%, 57%, and 40.7% in 2008, 2009, and 2010 respectively. In present study sensitivity was seen 100% (n=82) in colistin and polymyxin-B, 86.58% (n=71) in meropenem, 82.92% (n=68) in piperacillin-tazobactam, 68.29% (N=56) in tobramycin, 67.07% (n=55) in gentamicin, 64.63% (n=53) in amikacin, 58.58% (n=48) in piperacillin, 56.09% (n=46) in ceftazidime and 51.21% (n=42) in ciprofloxacin. And resistance was seen 80.48% (N=66) in co-trimoxazole, 82.92% (n=68) in cefixime, 59.75% (n=49) in cefoperazone/salbactam, 39.02% (n=32) in ciprofloxacin and 36.58% (n=30) in piperacillin. Similar results of sensitivity and resistance reported by Senthamarai S, 2014<sup>17</sup> and Gencer S, 2002<sup>18</sup> and various other research articles with slight variations in some antibiotics as it varies from one to another region based on the physiological and ecological conditions. MDR isolates are sensitive to antibiotics like colistin, polymyxin-B, and meropenem are reported in several studies for *Pseudomonas sp.* and other ESBL producing organisms like *Klebsiella sp.* by Negi S, 2020.<sup>19</sup> The total number of ESBL producing strains of *Pseudomonas sp.* in clinical samples was 30.48% in the present similar type of ESBL reported by Begum S, 2013.<sup>20</sup>

## 5. Conclusion

At the end of our study, we concluded that the most effective treatment for treating infections related

to *Pseudomonas sp.* in the Dewas region is colistin, polymyxin-B, meropenem, and piperacillin-tazobactam. Maximum isolates of *Pseudomonas sp.* obtained from hospitalized patients indicated nosocomial infections. It is very necessary to conduct routine surveillance for resistance strains at regular intervals of time to protect many lives from harmful MDR strains. Our study is an attempt to regulate the use of antibiotics that are irrelevant and wasteful. It is also a public health concern to take adequate measures, maintain cleanliness and hygiene to reduce the spread of nosocomial infections. To minimize the spread of hospital-acquired infections, it is the primary responsibility of all health care staff and all clinicians, and all patients along with their relatives to facilitate adequate handwashing with soap or sanitization of all areas. We can protect many lives from life-threatening MDR strains in this way and also aim to keep our society healthy.

## 6. Source of Funding

None.

## 7. Conflict of Interest

None.

## Acknowledgment

Authors are very thankful to all the staff members and technical staff of the Department of Microbiology, Amaltas Institute of Medical Sciences, Madhya Pradesh for their continuous support and help throughout the study.

## References

1. Chastre J. Problem pathogens (*Pseudomonas aeruginosa* and *Acinetobacter*). *Semin Respir Infect.* 2000;15(4):287–98. doi:10.1053/srin.2000.20944.
2. Obritsch MD, Fish DN, MacLaren R, Jung R. National Surveillance of Antimicrobial Resistance in *Pseudomonas aeruginosa* Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002. *Antimicrob Agent Chemother.* 2004;48:4606–10. doi:10.1128/aac.48.12.4606-4610.2004.
3. Gales AC, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program. *Diagn Microbiol Infect Dis.* 1997;44(3):301–11.
4. Weinstein RA, Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. *Clin Infectious Dis.* 2005;41(6):848–54.
5. Ruimy R, Genauzeau E, Barnabe C, Beaulieu A, Tibayrenc M, Andremont A. Genetic Diversity of *Pseudomonas aeruginosa* Strains Isolated from Ventilated Patients with Nosocomial Pneumonia, Cancer Patients with Bacteremia, and Environmental Water. *Infect Immun.* 2001;69(1):584–8. doi:10.1128/iai.69.1.584-588.2001.
6. Ahmad M, Hassan M, Khalid A, Tariq I, Asad MH, Samad A, et al. Prevalence of Extended Spectrum beta-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of *Pseudomonas* from

- Patients of Khyber Pakhtunkhwa, Pakistan. *BioMed Res Int.* 2016;2016:6068429. doi:10.1155/2016/6068429.
7. Bauer TM, Kirby AW, Sherris WM, Jc A, Bauer W. Susceptibility testing by a standardized single disc method. *Am J Clin.* 1966;45(4):493–499.
  8. Collee JG, Fraser AG, Marmion BP, Simmons A. Mackie & McCartney Practical Medical Microbiology. vol. 7. 14th ed.; 2008.
  9. Cheesbrough M. Medical laboratories manual for tropical countries. Tropical Health Technology and Butterworth London; 2002.
  10. Washington CW, Allen SD, Janda WM, Koneman EW, Procop GW, Schreckenbergerpc PC, et al. Koneman's Color Atlas and Textbook of Diagnostic Microbiology. Lippincott, Williams & Wilkins; 2006.
  11. Performance Standards for Antimicrobial Susceptibility Testing; Approved standard- Twenty-Fifth Informational Supplement ; 2015.
  12. Lee K, Chong Y, Shin H, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo- $\beta$ -lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clin Microbiol Infect.* 2001;7(2):88–91. doi:10.1046/j.1469-0691.2001.00204.x.
  13. Khan JA, Iqbal Z, Rahman SU, Farzana K, Khan A. Prevalence and resistance pattern of *pseudomonas aeruginosa* against various antibiotics. *Pak J Pharm Sci.* 2008;21(3):311–5.
  14. Mohanasoundaram KM. The antibiotic resistance pattern in the clinical isolates of *Pseudomonas aeruginosa* in a tertiary care hospital. *J Clin Diagn.* 2008;5(3):491–4.
  15. Chaudhury N, Mirza S, Misra RN, Paul R, Chaudhuri SS, Sen S. Isolation and identification of various *Pseudomonas* species from distinct clinical specimens and the study of their antibiogram. *Sch J App Med.* 2018;6(12):4964–76.
  16. Ullah N, Guler E, Guvenir M, Arkan A, Suer K. Isolation, identification, and antibiotic susceptibility patterns of *Pseudomonas aeruginosa* strains from various clinical samples in a University hospital in Northern Cyprus. *Cyprus J Med.* 2019;4(3):225–8.
  17. Senthamarai S. Resistance Pattern of *Pseudomonas aeruginosa* in a Tertiary Care Hospital of Kanchipuram, Tamilnadu, India. *J Clin Diagn Res.* 2014;8(5):30–2. doi:10.7860/jcdr/2014/7953.4388.
  18. Gencer S, Ak O, Benzonana N, Batirel A, Ozer S. Susceptibility patterns and cross resistances of antibiotics against *Pseudomonas aeruginosa* in a teaching hospital of Turkey. *Ann Clin Microbiol.* 2002;1(2). doi:10.1186/1476-0711-1-2.
  19. Negi S, Joshi M, Pahuja V, Bala L. Antibiotic Resistance Pattern of *Klebsiella* sp. At Tertiary Care Centre From Garhwal Himalayan Region. *Ann Int Med Den Res.* 2021;7(1):6–10. doi:10.21276/aimdr.2020.7.1.MB2.
  20. Begum S, Salam A, Alam F, Begum N, Hassan P, Haq JA. Detection of extended spectrum beta-lactamase in *Pseudomonas* spp. isolated from two tertiary care hospitals in Bangladesh. *BMC Res Notes.* 2013;6(1):7. doi:10.1186/1756-0500-6-7.

### Author biography

**Sandeep Negi**, Research Scholar

**Ramanath K**, Associate Professor

**Lakshmi Bala**, Professor

**Munesh Kumar Sharma**, Assistant Professor

**Cite this article:** Negi S, Ramanath K, Bala L, Sharma MK. Antibiotic susceptibility patterns of *Pseudomonas* sp. isolated from various clinical samples at a tertiary care hospital at Dewas in Madhya Pradesh, India. *Indian J Microbiol Res* 2021;8(1):65-70.